COMPANY OVERVIEW

Toragen, Inc. is targeting the root cause of virally induced cancers.

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

https://toragen.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Jun 30, 2023

Toragen, Inc. Announces Initiation of Phase 1 Trial of TGN-S11 in Patients with Human Papillomavirus-Induced Cancer

Feb 28, 2023

Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers

Feb 8, 2023

Toragen, Inc. Announces Appointment of Chief Scientific Officer

Oct 7, 2022

Toragen, Inc. Announces Chief Medical Officer to Drive the Company’s Clinical Development

Sep 30, 2022

Toragen, Inc. Announces Raising $5.4M in a Series Seed Round

For More Press Releases

---